Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
PTGER3 Biologics Sequence Review Report 2026: Prostaglandin E2 receptor EP3 subtype Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTGER3 Biologics Sequence Review Report 2026: Prostaglandin E2 receptor EP3 subtype Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTGER3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PTGFR Biologics Sequence Review Report 2026: Prostaglandin F2-alpha receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTGFR Biologics Sequence Review Report 2026: Prostaglandin F2-alpha receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTGFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PTGER4 Biologics Sequence Review Report 2026: Prostaglandin E2 receptor EP4 subtype Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTGER4 Biologics Sequence Review Report 2026: Prostaglandin E2 receptor EP4 subtype Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTGER4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PRLHR Biologics Sequence Review Report 2026: Prolactin-releasing peptide receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PRLHR Biologics Sequence Review Report 2026: Prolactin-releasing peptide receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PRLHR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PTGER1 Biologics Sequence Review Report 2026: Prostaglandin E2 receptor EP1 subtype Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTGER1 Biologics Sequence Review Report 2026: Prostaglandin E2 receptor EP1 subtype Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTGER1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PTAFR Biologics Sequence Review Report 2026: Platelet-activating factor receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PTAFR Biologics Sequence Review Report 2026: Platelet-activating factor receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTAFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OR1F1 Biologics Sequence Review Report 2026: Olfactory receptor 1F1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OR1F1 Biologics Sequence Review Report 2026: Olfactory receptor 1F1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OR1F1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OXTR Biologics Sequence Review Report 2026: Oxytocin receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OXTR Biologics Sequence Review Report 2026: Oxytocin receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OXTR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OR2A4 Biologics Sequence Review Report 2026: Olfactory receptor 2A4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OR2A4 Biologics Sequence Review Report 2026: Olfactory receptor 2A4 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OR2A4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OPRL1 Biologics Sequence Review Report 2026: Nociceptin receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OPRL1 Biologics Sequence Review Report 2026: Nociceptin receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OPRL1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OR1D2 Biologics Sequence Review Report 2026: Olfactory receptor 1D2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OR1D2 Biologics Sequence Review Report 2026: Olfactory receptor 1D2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OR1D2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
OPRM1 Biologics Sequence Review Report 2026: Mu-type opioid receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
OPRM1 Biologics Sequence Review Report 2026: Mu-type opioid receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of OPRM1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →